SAN DIEGO, Nov. 21, 2011 (GLOBE NEWSWIRE) -- Apricus Biosciences, Inc. (“Apricus Bio” or the “Company”) (Nasdaq:APRI - News) announced today that Kleanthis G. Xanthopoulos, Ph.D., President and Chief Executive Officer of Regulus Therapeutics Inc. (“Regulus”), has been appointed to the Company’s Board of Directors, effective immediately. Prior to joining Regulus in 2007, Dr. Xanthopoulos was the Managing Director of Enterprise Partners Venture Capital. He co-founded Anadys Pharmaceuticals, served as President and Chief Executive Officer from 2000 to 2006, and remained a Director until its acquisition by Roche in 2011. Before that, Dr. Xanthopoulos was Vice President at Aurora Biosciences (acquired by Vertex Pharmaceuticals) from 1997 to 2000, and Section Head of the National Human Genome Research Institute from 1995 to 1997.
